Systematic review suggests modest risk reduction with SGLT2 inhibitors or ARNIs added to standard therapy in severe heart failureModerate evidence supports adding SGLT2 inhibitors to heart failure treatment

This research matters for patients with severe heart failure with reduced ejection fraction. These patients often take multiple medications to manage their condition. Doctors want to know if adding new drugs helps them live longer or avoid hospital visits. This study looked at whether adding specific new medicines to standard care makes a difference. The standard care involves neurohormonal inhibitors, which are the usual first-line treatments for this condition. The researchers wanted to see if adding Angiotensin receptor-neprilysin inhibitors or Sodium-glucose cotransporter 2 inhibitors provided extra benefit. They combined data from many different studies to get a clearer picture of the results. This approach is called a network meta-analysis. It allows comparison of different treatment strategies at once. The analysis included 4,894 patients in total. This is a significant number that helps build confidence in the findings. The main goal was to see if adding these new drugs reduced the risk of a bad outcome. The bad outcome was defined as either dying from a cardiovascular cause or being hospitalized for heart failure. The researchers found that adding SGLT2 inhibitors was linked to a reduction in this risk. The specific measure of risk reduction was a hazard ratio of 0.87. This number means there was a 13 percent lower risk compared to taking standard care alone. The confidence interval for this result ranged from 0.75 to 1.01. This range suggests the result is statistically significant. When looking at Angiotensin receptor-neprilysin inhibitors, the results were different. Adding these drugs showed a hazard ratio of 0.96. This indicates a 4 percent lower risk. However, the confidence interval ranged from 0.83 to 1.12. Because this range includes 1.00, the result is not statistically significant. This means the study did not prove a clear benefit for this specific drug class in this analysis. The study did not report specific safety data or adverse events. It did not list how many patients stopped taking the drugs due to side effects. The certainty of the evidence was rated as moderate for SGLT2 inhibitors. For Angiotensin receptor-neprilysin inhibitors, the certainty was rated as low. This lower rating reflects the limited evidence available for their additive effects. The study authors explicitly state that treatment intensification should be approached with caution. Patients should not overstate the benefits based on this single analysis. The evidence for combining these drugs remains limited. This means doctors need to weigh the potential benefits against the risks carefully. For patients right now, this study offers some hope regarding SGLT2 inhibitors. It suggests these drugs might help reduce hospital visits or death when added to standard care. However, the results for the other drug type were not clear. Patients should talk to their doctors about their specific situation. Doctors will consider the individual patient history before making changes to medication lists. This research helps guide future decisions but does not change current guidelines immediately.